Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Genome editing company Editas Medicine nets $101mm in IPO

Executive Summary

Editas Medicine Inc. netted $101mm in its IPO of 6.8mm shares (including full exercise of the 885k overallotment option) at $16 per share. Proceeds will be used to fund the company's trials for LCA10 (Leber congenital amaurosis type 10; genetic progressive form of blindness), for preclinical studies with the candidate under its Juno Therapeutics collaboration (entered into in May 2015), and for expansion of platform technology.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register